Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Sponsor: University of California, Davis

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT07250477

Patient View

This phase 2 study randomizes advanced NSCLC patients to either a proteomic-guided therapy arm or a standard care arm. Eligibility includes metastatic NSCLC, ECOG ≤ 2, and age ≥18. The intervention uses PROphet CB and CARG-TT assessments to guide treatment, while the SOC arm follows standard biomarker testing. The primary endpoint is 12-month PFS.

Patient Parameters

Program Overview

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

Description

Participants will be randomized to an intervention arm or a standard of care (SOC) arm. Participants in the intervention arm will undergo pretreatment assessment with PROphet Clinical Benefit (CB) and the Cancer and Aging Research Group Toxicity Tool (CARG-TT); data from the assessments will be used to select systemic therapy, which can be any SOC treatment that incorporates a Programmed death-ligand 1 (PD-(L)1) antibody with or without chemotherapy and/or with or without Cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody. Participants in the SOC arm will undergo SOC biomarker assessment and subsequent selection of SOC systemic therapy. The primary endpoint is 12-month progression free survival (PFS). The findings will be stratified according to participant performance status and tumor PD-L1 score. The hypothesis is that risk-adapted, proteomic-guided systemic therapy will improve PFS among patients with previously untreated advanced NSCLC compared to SOC systemic therapy.

Eligibility Criteria

Inclusion Criteria

  • Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to receive standard of care immune checkpoint inhibitor-based therapy given with palliative intent.
  • Age ≥18 years at the time of consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥50%).
  • Ability to understand and willingness to sign the informed consent form (ICF).
  • Stated ability and willingness to adhere to all protocol requirements while on study

Exclusion Criteria

  • Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1.
  • Medical comorbidities precluding immune checkpoint inhibitor-based therapy per treating investgator's discretion.
  • Previous systemic therapy for metastatic Stage IIIC or IV NSCLC. Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion.
  • Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on study

Get This Program In Your Inbox

You can sign up and apply your patients for this program.